Literature DB >> 31967368

p62 promotes bladder cancer cell growth by activating KEAP1/NRF2-dependent antioxidative response.

Tao Li1,2, Dali Jiang1, Kaijie Wu1.   

Abstract

p62 is associated with 2 major cellular defense mechanisms against metabolic and oxidative stress, autophagy and the Kelch-like ECH-associated protein 1 (KEAP1)-nuclear factor-E2-related factor 2 (NRF2) system. Recent studies indicate that the p62-KEAP1-NRF2 pathway promotes tumorigenesis and tumor growth mediated by NRF2-dependent antioxidative response. However, whether p62 is involved in bladder cancer (BCa) development remains unknown. Here, we found that p62 is overexpressed in BCa tissue and several BCa cell lines. The knockdown of p62 inhibits BCa cell growth both in vitro and in vivo, with increased intracellular reactive oxygen species level. Mechanically, p62 activates NRF2 signaling by sequestrating KEAP1, which leads to the upregulation of antioxidant genes (Gclc, Gstm5, and Gpx2), thus protecting BCa cells from oxidative stress. Our findings indicate that p62 might be involved in the development of BCa and serve as a potential therapeutic target.
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  KEAP1; NRF2; bladder cancer; oxidative stress; p62

Year:  2020        PMID: 31967368     DOI: 10.1111/cas.14321

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  16 in total

Review 1.  The beginning of GPX2 and 30 years later.

Authors:  R Steven Esworthy; James H Doroshow; Fong-Fong Chu
Journal:  Free Radic Biol Med       Date:  2022-07-05       Impact factor: 8.101

2.  NRF2: KEAPing Tumors Protected.

Authors:  Ray Pillai; Makiko Hayashi; Anastasia-Maria Zavitsanou; Thales Papagiannakopoulos
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

Review 3.  p62: Friend or Foe? Evidences for OncoJanus and NeuroJanus Roles.

Authors:  Sonia Emanuele; Marianna Lauricella; Antonella D'Anneo; Daniela Carlisi; Anna De Blasio; Diana Di Liberto; Michela Giuliano
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

4.  Autophagy blockage promotes the pyroptosis of ox-LDL-treated macrophages by modulating the p62/Nrf2/ARE axis.

Authors:  Jiaru Liu; Chao Wang; Jiashan Li; Ying Yu; Yuee Liu; Huihui Liu; Qi Peng; Xiuru Guan
Journal:  J Physiol Biochem       Date:  2021-04-22       Impact factor: 4.158

5.  ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21.

Authors:  Minhua Deng; Wensu Wei; Jinling Duan; Rixin Chen; Ning Wang; Leye He; Yulu Peng; Xiaodan Ma; Zeshen Wu; Jianye Liu; Zhiyong Li; Zhiling Zhang; Lijuan Jiang; Fangjian Zhou; Dan Xie
Journal:  Cancer Sci       Date:  2021-03-09       Impact factor: 6.716

Review 6.  NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis.

Authors:  Holly Robertson; Albena T Dinkova-Kostova; John D Hayes
Journal:  Cancers (Basel)       Date:  2020-12-02       Impact factor: 6.639

Review 7.  The Pathways Underlying the Multiple Roles of p62 in Inflammation and Cancer.

Authors:  Paulina Hennig; Gabriele Fenini; Michela Di Filippo; Tugay Karakaya; Hans-Dietmar Beer
Journal:  Biomedicines       Date:  2021-06-22

8.  Development of a Gene Risk Signature for Patients of Pancreatic Cancer.

Authors:  Tao Liu; Long Chen; Guili Gao; Xing Liang; Junfeng Peng; Minghui Zheng; Judong Li; Yongqiang Ye; Chenghao Shao
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

Review 9.  Contrast effects of autophagy in the treatment of bladder cancer.

Authors:  Ece Konac; Yener Kurman; Sümer Baltaci
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-20

Review 10.  Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma.

Authors:  Hui Xie; Felix K-H Chun; Jochen Rutz; Roman A Blaheta
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.